Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies

Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAF(V600)-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with im...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei L., Gouw, Launce, Sabripour, Mahyar, Hwu, Wen-Jen, Benjamin, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429591/
https://www.ncbi.nlm.nih.gov/pubmed/22934279
http://dx.doi.org/10.4161/onci.19729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429591/
https://www.ncbi.nlm.nih.gov/pubmed/22934279
http://dx.doi.org/10.4161/onci.19729

Ejemplares similares